Evaluating the Diagnostic and Prognostic Value of Peripheral Immune Markers in Glioma Patients: A Prospective Multi-Institutional Cohort Study of 1282 Patients

Jie Lu,1,* Zhi-Yun Zhang,2,* Sheng Zhong,1,* Davy Deng,3,* Wen-Zhuo Yang,1,* Su-Wen Wu,1 Ye Cheng,4 Yang Bai,2 Yong-Gao Mou1 1Department of Neurosurgery/Neuro-Oncology, State Key Laboratory of Oncology in South China, Guangdong Provincial C...

Full description

Saved in:
Bibliographic Details
Main Authors: Lu J, Zhang ZY, Zhong S, Deng D, Yang WZ, Wu SW, Cheng Y, Bai Y, Mou YG
Format: Article
Language:English
Published: Dove Medical Press 2025-06-01
Series:Journal of Inflammation Research
Subjects:
Online Access:https://www.dovepress.com/evaluating-the-diagnostic-and-prognostic-value-of-peripheral-immune-ma-peer-reviewed-fulltext-article-JIR
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849417908488241152
author Lu J
Zhang ZY
Zhong S
Deng D
Yang WZ
Wu SW
Cheng Y
Bai Y
Mou YG
author_facet Lu J
Zhang ZY
Zhong S
Deng D
Yang WZ
Wu SW
Cheng Y
Bai Y
Mou YG
author_sort Lu J
collection DOAJ
description Jie Lu,1,* Zhi-Yun Zhang,2,* Sheng Zhong,1,* Davy Deng,3,* Wen-Zhuo Yang,1,* Su-Wen Wu,1 Ye Cheng,4 Yang Bai,2 Yong-Gao Mou1 1Department of Neurosurgery/Neuro-Oncology, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-Sen University Cancer Center, Guangzhou, 510060, People’s Republic of China; 2Department of Plastic and Reconstructive Surgery, The First Hospital of Jilin University, Changchun, People’s Republic of China; 3Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, 02115, USA; 4Department of Neurosurgery, Xuanwu Hospital Capital Medical University, Beijing, People’s Republic of China*These authors contributed equally to this workCorrespondence: Yong-Gao Mou; Yang Bai, Email mouyg_sysucc@126.com; baiyang0221@jlu.edu.cnObjective: Glioma is the most common primary brain tumor, with a specific immune microenvironment and aggressive nature. Novel systemic immune-inflammation indices (nSII) are the most comprehensive non-invasive biomarkers that represent patients’ peripheral immune status, which are urgently needed to improve clinical management. However, the diagnostic and prognostic value of nSII in glioma remains unknown.Methods: From October 2006 to April 2022, 1282 patients with primary glioma were enrolled. The preoperative peripheral blood samples were collected. Correlations between novel systemic immune-inflammation indices (nSII) and glioma grades and subtypes were analyzed using ANOVA, T-test, and ordinal logistic regression. The Cox regression model, K-M survival analysis, etc. were used to study the relationship between nSII and patients’ clinical outcomes.Results: With the higher clinical grade, the percentage of NK cells increases while Th lymphocytes and T lymphocytes decrease. The percentage of NK and Th cells was also correlated with glioma subtypes. In glioblastoma patients, the higher percentage of immunoglobulin light chains was associated with a favorable prognosis, whereas the higher percentage of B lymphocytes was associated with a poor prognosis. Our study showed high diagnostic potential, eg, combined model (C4 & NK & B cells) AUC 0.879 (grade I vs IV), combined model (Th & NK & T cells) AUC 0.845 (grade II vs IV), and combined model (C4 & NK & T cells) AUC 0.711 (grade III vs IV).Conclusion: The nSII can serve as a robust non-invasive diagnostic and prognostic biomarker in glioma, thus promoting clinical management in screening, stratification, and treatment optimization. This study also provides a comprehensive perspective on glioma’s systemic and intracranial immune landscape, paving the way for future translational applications.Keywords: glioma, peripheral blood, lymphocyte subsets, immunoglobulin, inflammatory cytokine
format Article
id doaj-art-50e34cf915ef49fca8a4ea87eb4cbf34
institution Kabale University
issn 1178-7031
language English
publishDate 2025-06-01
publisher Dove Medical Press
record_format Article
series Journal of Inflammation Research
spelling doaj-art-50e34cf915ef49fca8a4ea87eb4cbf342025-08-20T03:32:36ZengDove Medical PressJournal of Inflammation Research1178-70312025-06-01Volume 18Issue 174777492103749Evaluating the Diagnostic and Prognostic Value of Peripheral Immune Markers in Glioma Patients: A Prospective Multi-Institutional Cohort Study of 1282 PatientsLu J0Zhang ZYZhong S1Deng D2Yang WZ3Wu SW4Cheng Y5Bai Y6Mou YG7Neurosurgery/Neuro-OncologyDepartment of NeurosurgeryDepartment of Cancer BiologyDepartment of Neurosurgery/Neuro-OncologyDepartment of Thoracic SurgeryDepartment of NeurosurgeryDepartment of NeurosurgeryNeurosurgery/Neuro-OncologyJie Lu,1,* Zhi-Yun Zhang,2,* Sheng Zhong,1,* Davy Deng,3,* Wen-Zhuo Yang,1,* Su-Wen Wu,1 Ye Cheng,4 Yang Bai,2 Yong-Gao Mou1 1Department of Neurosurgery/Neuro-Oncology, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-Sen University Cancer Center, Guangzhou, 510060, People’s Republic of China; 2Department of Plastic and Reconstructive Surgery, The First Hospital of Jilin University, Changchun, People’s Republic of China; 3Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, 02115, USA; 4Department of Neurosurgery, Xuanwu Hospital Capital Medical University, Beijing, People’s Republic of China*These authors contributed equally to this workCorrespondence: Yong-Gao Mou; Yang Bai, Email mouyg_sysucc@126.com; baiyang0221@jlu.edu.cnObjective: Glioma is the most common primary brain tumor, with a specific immune microenvironment and aggressive nature. Novel systemic immune-inflammation indices (nSII) are the most comprehensive non-invasive biomarkers that represent patients’ peripheral immune status, which are urgently needed to improve clinical management. However, the diagnostic and prognostic value of nSII in glioma remains unknown.Methods: From October 2006 to April 2022, 1282 patients with primary glioma were enrolled. The preoperative peripheral blood samples were collected. Correlations between novel systemic immune-inflammation indices (nSII) and glioma grades and subtypes were analyzed using ANOVA, T-test, and ordinal logistic regression. The Cox regression model, K-M survival analysis, etc. were used to study the relationship between nSII and patients’ clinical outcomes.Results: With the higher clinical grade, the percentage of NK cells increases while Th lymphocytes and T lymphocytes decrease. The percentage of NK and Th cells was also correlated with glioma subtypes. In glioblastoma patients, the higher percentage of immunoglobulin light chains was associated with a favorable prognosis, whereas the higher percentage of B lymphocytes was associated with a poor prognosis. Our study showed high diagnostic potential, eg, combined model (C4 & NK & B cells) AUC 0.879 (grade I vs IV), combined model (Th & NK & T cells) AUC 0.845 (grade II vs IV), and combined model (C4 & NK & T cells) AUC 0.711 (grade III vs IV).Conclusion: The nSII can serve as a robust non-invasive diagnostic and prognostic biomarker in glioma, thus promoting clinical management in screening, stratification, and treatment optimization. This study also provides a comprehensive perspective on glioma’s systemic and intracranial immune landscape, paving the way for future translational applications.Keywords: glioma, peripheral blood, lymphocyte subsets, immunoglobulin, inflammatory cytokinehttps://www.dovepress.com/evaluating-the-diagnostic-and-prognostic-value-of-peripheral-immune-ma-peer-reviewed-fulltext-article-JIRGliomaPeripheral bloodLymphocyte subsetsImmunoglobulinInflammatory cytokine
spellingShingle Lu J
Zhang ZY
Zhong S
Deng D
Yang WZ
Wu SW
Cheng Y
Bai Y
Mou YG
Evaluating the Diagnostic and Prognostic Value of Peripheral Immune Markers in Glioma Patients: A Prospective Multi-Institutional Cohort Study of 1282 Patients
Journal of Inflammation Research
Glioma
Peripheral blood
Lymphocyte subsets
Immunoglobulin
Inflammatory cytokine
title Evaluating the Diagnostic and Prognostic Value of Peripheral Immune Markers in Glioma Patients: A Prospective Multi-Institutional Cohort Study of 1282 Patients
title_full Evaluating the Diagnostic and Prognostic Value of Peripheral Immune Markers in Glioma Patients: A Prospective Multi-Institutional Cohort Study of 1282 Patients
title_fullStr Evaluating the Diagnostic and Prognostic Value of Peripheral Immune Markers in Glioma Patients: A Prospective Multi-Institutional Cohort Study of 1282 Patients
title_full_unstemmed Evaluating the Diagnostic and Prognostic Value of Peripheral Immune Markers in Glioma Patients: A Prospective Multi-Institutional Cohort Study of 1282 Patients
title_short Evaluating the Diagnostic and Prognostic Value of Peripheral Immune Markers in Glioma Patients: A Prospective Multi-Institutional Cohort Study of 1282 Patients
title_sort evaluating the diagnostic and prognostic value of peripheral immune markers in glioma patients a prospective multi institutional cohort study of 1282 patients
topic Glioma
Peripheral blood
Lymphocyte subsets
Immunoglobulin
Inflammatory cytokine
url https://www.dovepress.com/evaluating-the-diagnostic-and-prognostic-value-of-peripheral-immune-ma-peer-reviewed-fulltext-article-JIR
work_keys_str_mv AT luj evaluatingthediagnosticandprognosticvalueofperipheralimmunemarkersingliomapatientsaprospectivemultiinstitutionalcohortstudyof1282patients
AT zhangzy evaluatingthediagnosticandprognosticvalueofperipheralimmunemarkersingliomapatientsaprospectivemultiinstitutionalcohortstudyof1282patients
AT zhongs evaluatingthediagnosticandprognosticvalueofperipheralimmunemarkersingliomapatientsaprospectivemultiinstitutionalcohortstudyof1282patients
AT dengd evaluatingthediagnosticandprognosticvalueofperipheralimmunemarkersingliomapatientsaprospectivemultiinstitutionalcohortstudyof1282patients
AT yangwz evaluatingthediagnosticandprognosticvalueofperipheralimmunemarkersingliomapatientsaprospectivemultiinstitutionalcohortstudyof1282patients
AT wusw evaluatingthediagnosticandprognosticvalueofperipheralimmunemarkersingliomapatientsaprospectivemultiinstitutionalcohortstudyof1282patients
AT chengy evaluatingthediagnosticandprognosticvalueofperipheralimmunemarkersingliomapatientsaprospectivemultiinstitutionalcohortstudyof1282patients
AT baiy evaluatingthediagnosticandprognosticvalueofperipheralimmunemarkersingliomapatientsaprospectivemultiinstitutionalcohortstudyof1282patients
AT mouyg evaluatingthediagnosticandprognosticvalueofperipheralimmunemarkersingliomapatientsaprospectivemultiinstitutionalcohortstudyof1282patients